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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is associated with increased mortality. Delay in appropriate antimicrobial
therapy (DAAT) is an important risk factor for death, although confounding between carriage of MRSA and DAAT has not been resolved.
We studied the association of risk factors with mortality and searched for speciﬁc populations vulnerable to DAAT. We conducted a
case–control study comparing patients with MRSA bacteraemia who died during hospitalization (cases) with patients with MRSA bactera-
emia who survived (controls) in three medical centres in two states. Patients were identiﬁed using computerized hospital databases for
the years 2001–2005. Medical records were retrieved and various epidemiological data extracted. Bivariate and multivariate logistic
regression analyses were performed. Overall, 388 patients with MRSA bacteraemia were included, 164 cases and 224 controls. According
to bivariate analyses, cases were signiﬁcantly more likely than controls to (i) be older (>65 years), (ii) have transferred from an institu-
tion, (iii) have stayed in an ICU, (iv) have had more invasive devices, (v) have a poorer prognosis on admission, (vi) have higher disease
severity at the time of bacteraemia, and (vii) have a DAAT of ‡2 days. Upon multivariate analysis, among patients >65 years, DAAT was
signiﬁcantly associated with increased mortality (p 0.04). Furthermore, patients >65 years with severe sepsis were much more likely to
experience DAAT (p 0.02). In elderly patients with MRSA bacteraemia, DAAT is associated with increased mortality. Moreover, advanced
age is a predictor for DAAT. These signiﬁcant epidemiological associations mandate early coverage of MRSA in septic elderly patients.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) ﬁrst
emerged in the 1960s, and since then its incidence has risen
continually worldwide [1–5]. In recent years, a large increase
has been observed among outpatients. It reﬂects the spread
of nosocomial strains outside of the hospital settings and the
emergence of novel community-acquired strains, causing
infections mostly in otherwise healthy people without any
contact with a healthcare institution [1–4,6]. According to
recent data from the National Healthcare Safety Network,
the pooled MRSA proportion among all S. aureus clinical iso-
lates is 56.2% [7].
Infections caused by MRSA are associated with adverse
outcomes compared with methicillin-sensitive Staphylococcus
aureus (MSSA) infections [3]. This may be related to: (i) dif-
ferences in vulnerability of the affected populations [8–14];
(ii) differences in strain virulence; (iii) differences in efﬁcacy
of treatment (various studies suggest that vancomycin, the
most commonly prescribed agent for MRSA infections, is less
effective than semisynthetic penicillins [15]); and (iv) differ-
ences in delay of appropriate antimicrobial therapy (DAAT),
which could lead to increased mortality, length of hospitaliza-
tion, and costs [16]. Patients with MRSA infection have been
shown to experience DAAT more often than those with
MSSA infection [16–22].
Previous studies allowed conclusions to be drawn by com-
paring mortality in patients with MRSA infections with mor-
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tality in patients belonging to other control groups, which
may lead to residual confounding associated with risks of
MRSA carriage such as older age, comorbidities, and other
less well-deﬁned factors. To avoid this likely confounding, we
used a different study design, i.e. a case–control study, to
identify reliably factors associated with mortality.
Materials and Methods
Settings
A multicentre case–control study comparing patients with
MRSA bacteraemia who died during the index hospitalization
(cases) with patients with MRSA bacteraemia who survived
(controls) was conducted during the years 2001–2005 in
three participating centres: (i) Beth Israel Deaconess Medical
Center (Boston, MA, USA); (ii) Duke University Medical
Center (Durham, NC, USA); and (iii) Tufts-New England
Medical Center (Boston, MA, USA). All centres are large
tertiary teaching hospitals.
All S. aureus bloodstream isolates submitted to the
microbiology laboratories of the participating centres were
identiﬁed to the species level and tested for susceptibility to
antibiotics according to the CLSI criteria [23].
Study design
A retrospective case–control study design was used. Patients
with MRSA bacteraemia were identiﬁed using the local
computerized databases in each hospital. Patients were then
classiﬁed as cases or controls based on discharge status,
i.e. fatality/survival. Medical records were retrieved and data
extracted into a prepared questionnaire. The parameters
recorded included demographics, comorbidities, severity of
illness, functional status, transfer from institution, admission
to ICUs, surgical procedures, antibiotic consumption, pros-
thetic devices, source of bacteraemia, removal of the source
of bacteraemia, and the presence of sepsis at the time of
diagnosis. The exact delays between onset of symptoms,
obtaining blood cultures, and the time appropriate treatment
was given were determined. All data were extracted into
a uniform questionnaire using a data management system
(Access; Microsoft Corp., Redmond, WA, USA).
Deﬁnitions
For the purpose of this study we used the following deﬁni-
tions: bacteraemia was deﬁned as the presence of at least
one blood culture growing MRSA; previous surgery was
deﬁned as an operation within the month prior to the onset
of MRSA bacteraemia. The level and severity of comorbidi-
ties were assessed according to the Charlson chronic com-
orbidity score [23]; the severity of illness was calculated
according to prognosis as reﬂected by the McCabe score
[24]; and the clinical severity of the bacteraemia episode was
assessed according to the Pitt bacteraemia score [25].
The functional status of patients was deﬁned according
to the criteria set by Katz et al. [26]. The source of bacter-
aemia was determined using the following deﬁnitions: a
catheter was considered to be the source of bacteraemia if
(i) quantitative culture of blood or semiquantitative culture
of a catheter segment conﬁrmed catheter-related infection
according to CDC criteria [27]; (ii) the culture of a speci-
men with purulent drainage from the insertion site or from
the tip of the removed catheter yielded MRSA that had the
same resistance phenotype as the cultured strain from the
peripheral blood; and (iii) no other source of bacteraemia
existed.
Pneumonia was considered to be the source of bactera-
emia if the patient had clinical symptoms and signs of a lower
respiratory tract infection, and if there was radiological evi-
dence of pulmonary inﬁltrates not attributable to other
causes [28]. Soft-tissue infection was considered to be the
source of bacteraemia when patients had a pure culture of
MRSA from a tissue or a drainage specimen from the
affected site and had signs of infection [29].
Surgical wound infection was deﬁned according to the
deﬁnitions of the CDC [29]. Infective endocarditis was
deﬁned according to Duke’s criteria [30]. Only in cases
where endocarditis was diagnosed together with the
bacteraemia was endocarditis designated as the source of
bacteraemia. Otherwise, endocarditis was considered to be
the result, not the source, of the bacteraemia. If a primary
focus of infection could not be determined, it was con-
sidered to be unknown. The sources of bacteraemia were
divided into two categories: removable and non-removable
foci. Removable sources included surgically removable infec-
tions or drainable abscesses and indwelling foreign bodies,
such as peripheral and central intravenous catheters. Non-
removable sources included unknown primary sites, pneu-
monia, and osteomyelitis or arthritis not related to a pros-
thetic device infection [31]. DAAT was calculated according
to the number of calendar days between the time blood
cultures were obtained and appropriate treatment was
given, based on in vitro susceptibilities.
Ethical considerations
The study was approved by the Institutional Review Board of
each participating centre. Because no direct patient contact
was planned, the requirement for informed consent was
waived. The data were de-identiﬁed in each centre and only
then transferred for analysis.
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Statistical analysis
All analyses were performed using SAS software (SAS Insti-
tute, Cary, NC, USA). Bivariable analyses were performed
using Fisher’s exact test or the v2 test for categorical
variables and the independent samples t-test or the Wilco-
xon rank sum test for continuous variables.
Multivariable models were constructed using logistic
regression. The primary objective of the multivariable analy-
ses was to assess the independent impact of DAAT while
controlling for potential confounders. The secondary objec-
tive of these analyses was to identify other independent risk
factors for mortality. All variables with a p value <0.20 in bi-
variable analyses were submitted to multivariate analysis. A
stepwise selection procedure was used to select variables for
inclusion in the ﬁnal model. The ﬁnal selected model was
tested for confounding. If a covariate affected the ß-coefﬁ-
cient of DAAT or another selected variable in the model by
>10%, then the confounding variable was maintained in the
multivariable model. All p values were two-sided. In addition
to examining statistical signiﬁcance and confounding, the
effect modiﬁcation among variables was evaluated by testing
appropriate interaction terms for statistical signiﬁcance.
When effect modiﬁcation was detected, subgroup analysis
was performed. Co-linearity was examined by replacing vari-
ables with each other and examining the effect on the model.
Results
Overall, 388 patients with MRSA bacteraemia were included in
the study: 164 (42%) who died, i.e. cases, and 224 (58%) who
survived, i.e. controls. There were no signiﬁcant differences in
mortality rates among the three participating centres.
Patient characteristics along with bivariate analysis results
are summarized in Table 1. Case patients were signiﬁcantly
older, were more often transferred from another institution,
had more invasive devices, and had a poorer prognosis as
evident by McCabe score [29] and Charlson score [25]. In
addition, cases had a greater severity of acute illness at the
time of bacteraemia as evident by parameters of severe sep-
sis and multiorgan dysfunction, by the Pitt bacteraemia score
[24], and by the frequency of admission to ICUs.
Analysis of modiﬁable factors, i.e. removal of the source
of infection, and of DAAT was performed. A removable
source of bacteraemia was evident in 44% of all patients, but
the source was less often removed among cases (18% vs.
28% by day 3, and 22% vs. 33% by day 5, among cases vs.
controls, respectively). The mean number of days from cul-
turing MRSA in blood to the beginning of antimicrobial ther-
apy of any kind, whether appropriate or inappropriate, did
not differ between groups. However, DAAT greater than
one calendar day tended to occur more often among cases
than controls.
Multivariate analysis revealed that after controlling for
potential confounders, including comorbidities before the
bacteraemia (Charlson score) and the acute severity of the
present illness (represented by the McCabe score, ICU stay
at time of bacteraemia, and the presence of severe sepsis),
poor functional status was associated with increased mortal-
ity risk (OR 1.45; 95% CI 1.05–2.02) as illustrated in Table 2.
In addition, both DAAT at day 2 and non-removal of the
TABLE 1. Bivariate analysis of risk factors for mortality
Variable
Cases:
n = 164 (%)
Controls:
n = 224 (%) OR p-value
Demographics
Mean age (years) ± SD 69.1 ± 17.8 61.3 ± 15.8 <0.001
Age >65 years 107 (65.2) 95 (42.4) 2.55 <0.001
Male gender 95 (57.9) 136 (60.7) 0.89 0.58
Transfer from institution 96 (58.5) 98 (42.9) 1.81 0.004
Comorbid conditions
Cardiovascular 105 (64) 112 (50) 1.78 0.006
Diabetes 56 (34.1) 77 (34.4) 0.99 0.96
Renal 49 (29.9) 52 (23.4) 1.41 0.14
Malignancy 39 (23.8) 45 (20.1) 1.18 0.52
Post transplantation 6 (3.7) 14 (6.3) 0.49 0.15
Lung 36 (22) 43 (19.2) 1.19 0.5
Hepatobiliary 27 (16.5) 24 (10.1) 1.64 0.098
AIDS 4 (2.4) 3 (1.3) 1.84 0.42
Immunosuppressive Rx 18 (11) 30 (13.4) 0.8 0.47
No. of comorbidities,
mean (SD)
2.23 (1.03) 1.96 (1.25) 0.1
Charlson comorbidity
score, mean (SD)
3.91 (2.24) 3.12 (2.28) 0.008
Foreign and prosthetic devices
Central line 70 (43.1) 117 (52.2) 0.67 0.05
Intubation 57 (34.8) 40 (17.8) 2.45 <0.001
Foley catheter 79 (48.2) 75 (33.5) 1.83 0.004
Prosthetic heart valve 12 (7.3) 8 (3.6) 1.95 0.15
Cardiac pacemaker 18 (11) 18 (8) 1.25 0.52
Vascular implants 21 (12.8) 27 (12.1) 0.97 0.92
Orthopaedic implants 11 (6.7) 22 (9.3) 0.6 0.18
Severity of illness
Multiple organ failure 12 (7.3) 5 (2.2) 3 0.04
Severe sepsis 69 (42.1) 33 (14.7) 4.2 <0.001
Pitt bacteraemia score,
mean (SD)
3.53 (2.41) 1.86 (1.71) <0.001
McCabe score <0.001
McCabe-1 60 29
McCabe-2 77 78
McCabe-3 27 115
Factors associated with hospitalization
Hospital days before
culture, mean (SD)
9.48 (6.8) 7.02 (4.87) 0.15
ICU stay before culture 67 (40.1) 48 (21.4) 2.54 <0.001
Surgery before culture 17 (10.4) 37 (16.5) 0.58 0.08
Ventilation before culture 29 (17.7) 23 (10.3) 1.67 0.1
No. of positive bacterial
culture, mean (SD)
1.95 (0.97) 1.81 (0.9) 0.15
Combination antibiotic
therapy
11 (6.7) 16 (7.1) 0.96 0.91
Source of bacteraemia
A removable source 67 (40.1) 105 (46.9) 0.73 0.13
Source removed by
day 3 after culture
29 (17.7) 63 (28.1) 0.55 0.02
Source removed by
day 5 after culture
36 (22) 73 (32.5) 0.58 0.02
Delay of appropriate therapy
Days from culture to
treatment (any), mean (SD)
0.21 (2.84) 0.21 (3.49) 0.98
1 calendar day of delay 47 (28.7) 51 (22.8) 1.36 0.19
2 calendar days of delay 31 (18.9) 28 (12.5) 1.6 0.08
3 calendar days of delay 22 (13.4) 23 (10.3) 1.35 0.34
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source of the bacteraemia tended to be associated with mor-
tality, although neither reached statistical signiﬁcance. How-
ever, there was a signiﬁcant effect modiﬁcation associated
with increased age, and among the 202 patients who were
>65 years of age, DAAT of >1 day was signiﬁcantly associated
with mortality (OR 2.35; 95% CI 1.01–5.44; Table 3).
Among 102 patients with severe sepsis, the only predictor
for mortality was DAAT, and the effect was most pro-
nounced for a delay of >1 day (delay of 1 day: OR 3.0, p
0.069; delay of >1 day: OR 9.7, p 0.032). We examined the
effect of age >65 years on the likelihood of DAAT. We
found that among elderly patients with severe sepsis there
was a much greater likelihood of DAAT when compared
with patients younger than 65 years with severe sepsis (25%
among the elderly vs. 6.5% among younger patients; OR
4.78; 95% CI 1.21–5.56; p 0.02). Among the 14 patients over
the age of 65 years with severe sepsis who experienced
DAAT of >1 day, 13 (93%) died, and among patients over
the age of 65 with severe sepsis for whom effective therapy
was not delayed for more than 1 day, 29 out of 42 (69%)
died (p 0.07).
Discussion
Bacteraemia caused by MRSA is a common and serious con-
dition, associated with high mortality. Identifying modiﬁable
risk factors for mortality are essential in order to apply
effective interventions to reduce mortality. Here, we elected
to address speciﬁcally the question as to which are the mod-
iﬁable factors associated with mortality among patients with
MRSA bacteraemia, and therefore used the case–control
methodology to reduce the risk of residual confounding
associated with group ascertainment. Upon bivariate analy-
ses, this large multicentre study identiﬁed two modiﬁable risk
factors for mortality: (i) a delay of ‡3 days in removing the
source of the bacteraemia; and (ii) DAAT of ‡2 days. Upon
multivariate analysis, source removal and DAAT tended to
be associated with mortality, although associations were not
signiﬁcant. In the subset of patients older than 65 years,
DAAT of ‡2 days was an independent, signiﬁcant predictor
of mortality.
DAAT is considered one of the most important modiﬁ-
able determinants of survival for patients with bacteraemia
[26]. In a study conducted with severe septic patients, each
hour of delayed therapy in the ﬁrst 6 h of infection was
associated with an average decrease in survival of 7.6% [17].
Previous studies that assessed DAAT speciﬁcally in S. aureus
infections in various clinical syndromes and scenarios also
showed correlation with increased mortality [16,19–22]. Our
study, conducted using a somewhat different methodology,
conﬁrms the impact of DAAT on mortality rates.
Removal of the source of the bacteraemia is also a factor
that inﬂuences mortality in various ways: removal might be as
simple as pulling out an intravenous line at bedside, or as com-
plex as removing hardware from infected joints in an operating
room. Thus, in some cases removal of hardware might be
associated with complex, severe infections and then might be
associated with increased risk of mortality. However, in a pre-
vious study of S. aureus bacteraemia cases, neither resistance
to methicillin nor DAAT had an impact on mortality in patients
with a removable source of infection, whereas among patients
with a non-removable source or a non-eradicated focus, both
MRSA and DAAT became signiﬁcantly associated with
increased mortality [32]. In another observational report, fail-
ure to remove lines in catheter-related bacteraemias was asso-
ciated with increased therapy failures [29]. These studies, in
addition to our ﬁndings that source removal was indepen-
dently associated with improved outcome, might reﬂect an
underestimation of the true effect of source removal, since
many patients who require hardware removal are severely ill
and have poor functional status.
Our analyses demonstrate that age is a strong modiﬁer of
the likelihood of DAAT being a risk factor for mortality. In
addition, we found that elderly, frail patients experience
more DAAT. It was interesting to see that DAAT was not
directly associated with the acute severity of illness, as
15–19% of patients in each of the McCabe score groups
experienced DAAT, a non-signiﬁcant difference. However,
the difference in DAAT among patients >65 years old was
signiﬁcantly greater in comparison with those <65 years old,
and this difference was even more signiﬁcant among patients
older than 80 years in comparison with patients younger
TABLE 2. Multivariate model for mortality
Variable Odds ratio p-value 95% CI
Functional status 1.45 0.026 1.05 2.02
McCabe score 0.49 0.000 0.35 0.70
Charlson score 1.15 0.013 1.03 1.28
ICU stay prior 1.76 0.040 1.02 3.01
Severe sepsis 3.16 0.000 1.84 5.41
Source remove by day 3 0.61 0.093 0.34 1.09
Delay in effective therapy at day 2 1.85 0.074 0.94 3.64
TABLE 3. Multivariate model for mortality among patients
older than 65 years
Variable Odds ratio p-value 95% CI
Functional status 1.48 0.078 0.96 2.29
McCabe score 0.44 0.001 0.27 0.70
Severe sepsis 3.10 0.003 1.48 6.50
Delay in effective therapy at day 2 2.35 0.047 1.01 5.44
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than 80 years (p 0.0025 between groups). As far as we
know, this study is the ﬁrst to report DAAT as a function of
age, which has interesting medical and ethical implications,
particularly since DAAT in the elderly population was inde-
pendently associated with increased mortality.
It is important to emphasize that DAAT is difﬁcult to assess
since it is usually measured as delay from the time of culture,
which is the best available parameter to use for the time of
onset of infection. If the actual time of onset of the infection
could be recorded, it would better reﬂect the actual delay
between infection onset and administration of effective
therapy. In our study 75% of all patients had received
appropriate empiric antibiotic therapy directed at MRSA and
had experienced no DAAT. This reﬂects practices where
MRSA is often suspected as the causative organism in bacte-
raemic patients. However, this may have limited our power to
investigate the role of DAAT in mortality.
To conclude, this analysis suggests that in-hospital mortal-
ity may be prevented by the administration as soon as possi-
ble of effective empiric therapy, especially in cases of severe
sepsis and in older patients, and by early removal of the
source of infection when possible. More than 10% of patients
in our cohort did not receive effective therapy even after
3 days of infection, when culture results were available. These
patients may have had improved outcome if appropriate ther-
apy had been initiated earlier. Although initiating appropriate
therapy early and removing the source of infection may be
considered by some to be a matter of ‘common knowledge
and practice’ for working physicians, these interventions
should be speciﬁcally addressed in the management of severe
infections, particularly among the elderly. Given the rapid
spread of MRSA in healthcare and community settings, our
data suggest a signiﬁcant opportunity for improving healthcare
outcomes. Future interventions should incorporate educa-
tion, rapid diagnostics and established protocols, in order to
improve the management of MRSA bloodstream infections.
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